Opiant Pharmaceuticals, Inc. (OPNT)

NASDAQ: OPNT · IEX Real-Time Price · USD
12.80
0.00 (0.00%)
Jul 5, 2022 12:00 AM EDT - Market open

Company Description

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose.

The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.

The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.

Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals Logo
Country United States
Founded 2005
Industry Pharmaceuticals
Sector Health Care
Employees 37

Contact Details

Address:
233 Wilshirre Boulevard
Santa Monica, CA 90401
United States
Phone 310 598 5410
Website opiant.com

Stock Details

Ticker Symbol OPNT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001385508
CUSIP Number 53224T105
ISIN Number US6837501039
Employer ID 46-4744124
SIC Code 8731

Key Executives

Name Position
Dr. Roger Crystal M.D. President, Chief Executive Officer and Director
David D. O'Toole Chief Financial Officer
Dr. Phillip Skolnick D.Sc. (hon), Ph.D. Chief Scientific Officer
Ben Atkins Vice President of Communications and Investor Relations
Brian Gorman Executive Vice President Corporate Development and General Counsel
Dr. Mark Heath Ellison Ph.D. Chief Development Officer
Matthew R. Ruth Chief Commercial Officer

Latest SEC Filings

Date Type Title
Jun 29, 2022 4 Statement of changes in beneficial ownership of securities
Jun 29, 2022 4 Statement of changes in beneficial ownership of securities
Jun 29, 2022 4 Statement of changes in beneficial ownership of securities
Jun 29, 2022 4 Statement of changes in beneficial ownership of securities
Jun 29, 2022 4 Statement of changes in beneficial ownership of securities
Jun 29, 2022 4 Statement of changes in beneficial ownership of securities
Jun 17, 2022 SC 13D/A General statement of acquisition of beneficial ownership
Jun 17, 2022 SC 13D/A General statement of acquisition of beneficial ownership
Jun 15, 2022 4 Statement of changes in beneficial ownership of securities
Jun 14, 2022 4 Statement of changes in beneficial ownership of securities